Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mild-to-moderate Alzheimer's Disease AND ALZHEIMER Disease AND MRI

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    74 result(s) found for: Mild-to-moderate Alzheimer's Disease AND ALZHEIMER Disease AND MRI. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2021-004809-40 Sponsor Protocol Number: GV1001-AD-CL2-007 Start Date*: 2022-10-10
    Sponsor Name:GemVax &KAEL Co., Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously ...
    Medical condition: Mild to Moderate (stage 4 and 5) Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) FR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) FI (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012748-17 Sponsor Protocol Number: ELN115727-301 Start Date*: 2010-03-11
    Sponsor Name:Janssen Alzheimer Immunotherapy
    Full Title: A phase 3, multicenter, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild to moderate Alzheimer's di...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011098-34 Sponsor Protocol Number: CR081101/CO14950 Start Date*: 2009-10-30
    Sponsor Name:JSW Lifesciences GmbH
    Full Title: A multicentre double-blind, placebo-controlled, randomised, parallel-group study to evaluate the efficacy and safety of Lornoxicam in patients with mild to moderate probable Alzheimer’s Disease.
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004675-35 Sponsor Protocol Number: AAB-001-251 Start Date*: 2007-08-20
    Sponsor Name:Elan Regulatory Holdings Ltd
    Full Title: A Phase II, Multicenter, Open-Label, Long-Term Treatment Study to Determine the Safety, Tolerability and Efficacy of AAB-001 (ELN115727) in Patients with Alzheimer's Disease who Participated in Stu...
    Medical condition: Mild to Moderate Alzheimers Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003659-63 Sponsor Protocol Number: BGC20-1259-04 Start Date*: 2009-03-13
    Sponsor Name:BTG International Ltd
    Full Title: A multicentre double-blind, placebo-controlled, randomised, parallel-group study to evaluate the safety and efficacy of BGC20-1259 in patients with mild to moderate probable Alzheimer’s Disease.
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001724-19 Sponsor Protocol Number: 2013/2 Start Date*: 2014-05-13
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
    Full Title: Pilot study to assess P-glycoprotein function at the blood-brain barrier of patients with mild to moderate Alzheimer's disease
    Medical condition: Alzheimer's disease and healthy controls (2 groups: 1 group with young healthy volunteers, 1 group with elderly healthy volunteers)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002326-27 Sponsor Protocol Number: COG0201 Start Date*: 2022-09-14
    Sponsor Name:Cognition Therapeutics, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CT1812 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
    Medical condition: Mild to Moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003552-36 Sponsor Protocol Number: COG0202 Start Date*: 2020-01-14
    Sponsor Name:Cognition Therapeutics, Inc.
    Full Title: A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects With Mild to Moderate Alzheimer’s Disease
    Medical condition: Mild to Moderate Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012179-82 Sponsor Protocol Number: B0401005 Start Date*: 2010-01-05
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2 MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF-04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-020427-43 Sponsor Protocol Number: B0401011 Start Date*: 2010-10-13
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2 MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF 04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE ON STABLE DONEPEZIL THERAPY
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002317-12 Sponsor Protocol Number: ACT10019 Start Date*: 2006-08-29
    Sponsor Name:Sanofi-aventis
    Full Title: A double-blind placebo-controlled study of the activity of AVE1625 at doses of 10 mg and 40mg for 12 weeks in patients with mild to moderate Alzheimer's Disease
    Medical condition: Mild to moderate Alzheimer Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001403-11 Sponsor Protocol Number: AVA102672 Start Date*: 2006-09-27
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition ...
    Medical condition: Alzheimers Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) ES (Completed) HU (Completed) AT (Completed) CZ (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001187-52 Sponsor Protocol Number: AX.- CL – 06a Start Date*: 2004-11-12
    Sponsor Name:Axonyx Corporation
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Two Different Dosages of Phenserine-tartrate in Patients with Mild to Moderate Probable Alzheimer’s Disea...
    Medical condition: Alzheimer’s Disease is a chronic progressive illness leading to loss of cognitive and intellectual abilities such as memory function, judgement and abstract thinking. In addition to the cognitive d...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10001896 Prim
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023322-21 Sponsor Protocol Number: NP031112-10B04 Start Date*: 2011-04-13
    Sponsor Name:Noscira S.A
    Full Title: A multicenter, Randomized, Double-blind, Placebo-controlled, 4-arm, 26 week Parallel-Group Study to evaluate the Efficacy, Safety and Tolerability of Two Oral Doses and Two Regimes of Tideglusib vs...
    Medical condition: Alzheimer's Disease (mild to moderate)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) FI (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006257-40 Sponsor Protocol Number: ACI-24-0701 Start Date*: 2009-12-09
    Sponsor Name:AC Immune SA
    Full Title: A Phase I/II Double-Blind, Randomised, Placebo-Controlled, Adaptive Design Study of the Safety, Tolerability, Immunogenicity and Efficacy of ACI-24 in Patients with Mild to Moderate Alzheimer's Dis...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-021218-50 Sponsor Protocol Number: AB09004 Start Date*: 2011-05-25
    Sponsor Name:AB Science
    Full Title: A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease
    Medical condition: mild to moderate Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012271 Dementia Alzheimer's type LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prohibited by CA) ES (Completed) SK (Prohibited by CA) PL (Completed) GR (Completed) GB (GB - no longer in EU/EEA) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002038-39 Sponsor Protocol Number: AVA105640 Start Date*: 2007-03-13
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition a...
    Medical condition: Mild to Moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) GR (Completed) EE (Completed) AT (Completed) HU (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-011172-30 Sponsor Protocol Number: A9951007 Start Date*: 2009-08-10
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2 DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS/ PHARMACODYNAMICS OF PF-04360365 IN MILD TO MODERATE ALZHEIMER’S...
    Medical condition: Mild to Moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005260-14 Sponsor Protocol Number: ACI-91-0801 Start Date*: 2008-11-26
    Sponsor Name:AC Immune SA
    Full Title: A double-blind placebo-controlled study of the safety, tolerability and efficacy of 12 months’ treatment with ACI-91 in patients with mild to moderate Alzheimer’s Disease
    Medical condition: Mild to moderate Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004117-33 Sponsor Protocol Number: H3B109689 Start Date*: 2007-12-17
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer's disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selec...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 21 12:39:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA